The head of a medical supplies company involved in the distribution and supply of monoclonal antibodies across southeastern and northeastern regions of the nation, told NTD in a Jan. 12 interview that government takeover of the monoclonal antibody supply chain has exacerbated backlogs and shortages.
“The way the products are being distributed right now, relying on the government to determine who gets what, that process can be very lengthy in terms of time,” Dealmed CEO Michael Einhorn said.
